Immune Targeting Systems (ITS) Ltd. Secures An £8.65m Series A Extension To Fund FP-01, Its Synthetic Universal Flu Vaccine Through Phase-II Studies
Submitted by MedicalReplies on Wednesday, 17 February 2010No Comment
Immune Targeting Systems (ITS) Limited (”ITS”), one of the leading developers of synthetic vaccines for mutating viruses, announced it had secured a Series-A equity funding round extension for £8.65m which brings the total Series A financing to £13.15m. The company’s key investors HealthCap (Sweden), London Technology Fund (UK), Novartis Venture Fund (US & Basel) and Truffle Capital (France) are all participating. The round will be kept open until mid-2010 for new potential investors to invest…
Leave your response!